Medpace Holdings (MEDP) climbed roughly 4% on Friday, April 25, 2026, extending a rebound move following a dramatic post-earnings reset earlier in the week. The bounce comes as traders and fundamental investors digest the April 22 Q1 2026 print and shift focus back to top-line growth and earnings power after the stock’s initial drop centered on bookings and forward-growth optics. (investor.medpace.com)

In Q1 2026, Medpace reported revenue of $706.6 million, up 26.5% year over year, alongside net income of $123.9 million. GAAP EPS was reported at $4.28, a notable beat versus widely cited consensus estimates, helping re-anchor the bull case that execution remains strong even as growth normalizes. (investor.medpace.com)

The key pressure point in the quarter was demand signaling: net new business awards were $618.4 million, producing a net book-to-bill ratio of 0.88x, meaning bookings trailed recognized revenue during the period. That metric helped trigger the initial negative reaction, but the stock’s move higher today suggests the market is increasingly treating the quarter as a debate over duration of growth rather than a breakdown in current operating performance. (investor.medpace.com)

Near-term trading is likely to remain sensitive to any incremental indicators on cancellations, bookings momentum, and backlog conversion, since book-to-bill has become the headline KPI for confidence in 2026 growth. Investors will also be watching for any follow-on estimate changes or fresh price-target actions as analysts update models based on the Q1 disclosures and full-year outlook framework. (investing.com)